Conagra (CAG) is down big, insiders are buying, and the dividend is near 9%. Is this a deep-value opportunity—or a trap in disguise? 🥫

Read entire article

Shoe Carnival (SCVL) is trading near lows with a $500K insider buy, high short interest, and ultra-cheap valuation. Is this a hidden value play—or a classic trap? 👟

Read entire article

CEOs, directors, and 10% owners are writing real checks again. From Oscar Health’s massive $11.9M buy to Nike’s continued dip-buying, here are the most interesting insider moves of April 2026.

Read entire article

Nike (NKE) has fallen sharply from its highs, but insider buying, strong brand equity, and improved valuation are turning heads. Is this the start of a comeback—or a trap?

Read entire article

Oscar Health (OSCR) is no longer just a flashy disruptor—it’s aiming for profitability. With CEO Mark Bertolini buying $11.9M in stock and revenue projected to hit $19B in 2026, this could be one of the most compelling turnaround plays in healthcare.

Read entire article

HMH just IPO’d… and insiders are already buying millions. From strong margins to a pivot into mining and geothermal, here’s why this overlooked energy stock is getting attention.

Read entire article

When CEOs, directors, and 10% owners buy millions of dollars of their own stock, it’s worth paying attention. Here are the top insider buys of April 2026—and why MGM, PANW, AHCO, and others stand out.

Read entire article

Phreesia just hit profitability—and got punished for it. With insiders loading up and institutions fully committed, is this a classic overreaction or a value trap? Let’s decode the dip.

Read entire article

IperionX is betting on a U.S. titanium comeback. With government backing and disruptive tech, the upside is huge—but so are the risks.

Read entire article

CME Group is the “house that always wins” in financial markets. A dominant, cash-generating business—but at current prices, patience may pay off.

Read entire article